Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT
NCT06028828Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in hematologic malignancy, sponsored by University of California, Irvine. Started Sep 2023; status: recruiting.
02
Drugs
melphalan
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06028828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028828.